• ECM Remodeling Drives Mitochondrial Fission via TGF-β Signal

  2026-06-25

  Zhang et al. (2024) uncover an evolutionarily conserved pathway where extracellular matrix (ECM) remodeling, specifically hyaluronan degradation, initiates mitochondrial fission and stress responses through TGF-β signaling. This ECM-mitochondria crosstalk enhances immune defense mechanisms and provides new avenues for mitochondrial dynamics research.

• Z-DEVD-FMK (SKU A1920): Reliable Caspase-3 Inhibitor Solutio

  2026-06-25

  This evidence-driven article addresses key workflow challenges in apoptosis and neuroprotection research, demonstrating how Z-DEVD-FMK (SKU A1920) delivers reproducible, mechanistically validated results. Practical Q&A scenarios guide researchers through protocol optimization, data interpretation, and reliable product selection, with a focus on leveraging the dual caspase/calpain inhibition of Z-DEVD-FMK for robust experimental outcomes.

• ATM Inhibition and Fenofibrate Synergy in Ovarian Cancer Mod

  2026-06-24

  This study identifies ATM kinase as a therapeutic vulnerability in high grade serous ovarian cancer (HGSOC) with homologous recombination proficiency. Combined ATM inhibition and fenofibrate treatment synergistically induce senescence in HGSOC cells, suggesting a metabolic strategy for overcoming therapy resistance.

• Leupeptin Hemisulfate Salt: Precision for Protease Activity

  2026-06-23

  Leupeptin hemisulfate salt sets the benchmark for reversible, nanomolar inhibition of serine and cysteine proteases—empowering reliable protein degradation, viral replication, and autophagy studies. This guide demystifies experimental workflows, troubleshooting strategies, and cross-domain applications, drawing on the latest advances in metabolic-epigenetic research.

• Asunaprevir (BMS-650032): Advanced HCV NS3 Protease Inhibiti

  2026-06-23

  Asunaprevir (BMS-650032) delivers potent, broad-spectrum HCV NS3 protease inhibition that streamlines hepatitis C research across diverse genotypes and cell models. This article details practical workflow enhancements, protocol parameters, and troubleshooting strategies to maximize experimental success with this APExBIO offering.

• Technical Use of Hoechst 33342/PI Double Staining Kit (K2237

  2026-06-22

  The Hoechst 33342/PI Double Staining Kit addresses the need for rapid, fluorescence-based differentiation of apoptotic, necrotic, and viable cells in research settings. It is suitable for microscopy or flow cytometry workflows but should not be used for diagnostic or clinical applications.

• SCUBE3 Antibody Targeting Suppresses Tumor Growth and Immuno

  2026-06-22

  This study identifies secretory protein SCUBE3 as a central driver of tumor progression and therapy resistance through oncogenic signaling and immune evasion. Antibody-mediated neutralization of SCUBE3 disrupts these processes, resulting in substantial tumor suppression and restored antitumor immunity, with implications for pan-cancer therapeutic strategies.

• Amplex Red in High-Precision Enzyme Activity and Redox Signa

  2026-06-21

  Explore how Amplex Red enables ultra-sensitive detection of hydrogen peroxide and peroxidase activity in advanced biochemical assays. This article uniquely focuses on optimizing assay reliability and practical protocol design for redox signaling studies using this fluorogenic probe.

• Reelin-SFK Pathway: A Gatekeeper for Ketamine’s Antidepressa

  2026-06-20

  This study uncovers a critical requirement for intact Reelin-Apoer2-Src family kinase (SFK) signaling in enabling the behavioral and synaptic effects of ketamine. By employing genetic and pharmacological approaches, the authors demonstrate that disruptions in this pathway may underlie nonresponsiveness to ketamine in treatment-resistant depression, with implications for both neurobiology and future assay development.

• Blocking Extracellular Vesicle Release in Triple-Negative Br

  2026-06-19

  McNamee et al. systematically evaluated the inhibition of extracellular vesicle (EV) release in triple-negative breast cancer (TNBC) cells using several compounds, including the ROCK inhibitor Y-27632 dihydrochloride. Their findings reveal that broad suppression of EV secretion—achievable with non-toxic inhibitor regimens—significantly limits the transmission of aggressive cancer traits via EVs, underscoring the therapeutic potential of targeting EV biogenesis in TNBC.

• Trolox: Protocol Optimization for Oxidative Injury Research

  2026-06-19

  Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) is the benchmark cell-permeable antioxidant for precise oxidative injury modeling and assay calibration. This article unpacks practical workflows, advanced troubleshooting, and key protocol parameters to maximize reproducibility in neurodegeneration and cancer biology research.

• HyperScript First-Strand cDNA Synthesis Kit: Precision for C

  2026-06-18

  Unlock robust and reproducible cDNA synthesis from even the most challenging RNA templates with the HyperScript First-Strand cDNA Synthesis Kit. Its engineered reverse transcriptase enables sensitive detection of low-abundance transcripts and seamless integration into PCR and qPCR workflows, setting a new benchmark for gene expression studies.

• Topotecan (SKF104864): Translational Insights for Pediatric

  2026-06-18

  Explore Topotecan’s dual role as a topoisomerase I inhibitor and translational tool in advanced cancer research. This article unveils unique evidence-based strategies for apoptosis induction in glioma cells and pediatric solid tumor models, offering new perspectives for assay optimization.

• Mitocytosis Inhibition Enhances Mitochondria-Targeted Antime

  2026-06-17

  This study uncovers how mitocytosis—a migrasome-mediated expulsion of damaged mitochondria—limits the efficacy of mitochondria-targeted therapies in metastatic breast tumor models. By engineering a dual-targeting nanoplatform to inhibit mitocytosis and induce mitochondrial damage, the authors demonstrate significantly improved antimetastatic effects, offering a new strategy for optimizing organelle-directed drug delivery.

• Trolox: Mechanistic Insights and Advanced Applications in Ox

  2026-06-17

  Explore how Trolox, a potent cell-permeable antioxidant, advances oxidative injury research by uniquely targeting lipid peroxidation and redox signaling. This article delivers mechanistic depth and practical guidance for assay design, setting it apart from standard protocol guides.

459 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page